A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
Phase of Trial: Phase IV
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Proof of concept; Therapeutic Use
- 27 Dec 2017 Planned number of patients changed from 11 to 40.
- 01 Feb 2017 Status changed from not yet recruiting to recruiting.
- 03 Nov 2016 New trial record